Imaging Biometrics secures patent for zero-dose imaging software

By staff writers

June 24, 2021 -- Advanced visualization software firm Imaging Biometrics (IB) announced it has secured a U.S. patent for its IB Zero G artificial intelligence (AI) software, which is designed to eliminate the need for gadolinium-based contrast agents in imaging exams.

IB Zero G accepts noncontrast medical images as inputs and produces a synthetic image series that mimics contrast-enhanced images of comparable diagnostic quality, IB said. Benefits include less time in the scanner for patients and for providers, an increase in scanner availability, and a reduction in gadolinium expense, the company reported.

IB Zero G AI software images
IB Zero G AI software images; (left) standard contrast and (right) zero contrast. Images courtesy of Imaging Biometrics.

IB Zero G is compatible with all MRI scanners, according to the firm.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking